MeTC7

CAS: 1817841-22-7 货号: M648616 分子式: C32H48BrN3O4 分子量: 618.65
有货
级别和纯度: ≥98%
储存条件
-20°C储存
运输条件
超低温运输
★
规格
库存
价格
数量
5mg
M648616-5mg
期货 Stock Image
¥1,400.90
10mg
M648616-10mg
期货 Stock Image
¥2,600.90
25mg
M648616-25mg
期货 Stock Image
¥5,200.90
50mg
M648616-50mg
期货 Stock Image
¥8,800.90
100mg
M648616-100mg
期货 Stock Image
¥15,000.90
请输入您要添加的产品数量
🧪
为什么选择此级别

提供 ≥98% 纯度,适用于对基线干扰要求严格的色谱和分析工作流程。

🌡

储存与运输

-20°C储存。超低温运输 。请查阅批次 COA 获取详细规格。

📋

质量文档

SDS、COA、产品数据表及规格说明书均可下载。可通过批号查询获取批次 COA。

📚

文献证明

在色谱分析、有机合成和交叉偶联反应领域已被 0 篇同行评审文献引用。

概述


MeTC7 is a Vitamin-D receptor (VDR) antagonist. MeTC7 has potent VDR inhibition activity with an IC 50 value of 2.9 μM. MeTC7 shows good antitumor effects

In Vitro

MeTC7 (compound 5) shows potent VDR inhibition activity with an IC 50 value of 2.9 μM. MeTC7 disrupts the VDR-Ligand-binding domain in Silico. MeTC7 (250 nM; 18 h) suppresses RXRα and Importin-4 expressions in the ovarian cancer cell-line. MeTC7 (250 nM; 18 h) inhibits the viability of ovarian cancer cells and induces PARP1 cleavage. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Western Blot AnalysisCell Line: 2008 cells Concentration: 250 nM Incubation Time: 18, 12 h Result: Reduced the expression of RXR-α, Importin-4 and increased cleaved PARP1 expression in 2008 cells. Cell Viability AssayCell Line: SKOV-3, IGROV-1, CAOV-3, OVCAR-3, OVCAR-8, and 2008 ovarian cancer cell-lines Concentration: 0, 0.25, 0.5, 0.75, 1.0, 1.25 μM Incubation Time: 24 h Result: Reduced the viability of SKOV-3, IGROV-1, CAOV-3, OVCAR-3, OVCAR-8, and 2008 ovarian cancer cell-lines.

In Vivo

MeTC7 (compound 5) (i.p.; 10 mg/kg) reduces the growth of the spontaneous transgenic TH-MYCN neuroblastoma and xenografts in vivo . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Mice Dosage: 10 mg/kg Administration: IP Result: Reduced the growth of xenografts derived from ovarian cancer, medulloblastoma, and pancreatic cancer cells. Inhibited the growth of neuroblastoma cells and Xenografts. Reduced MYCN expression and blocked the growth of TH-MYCN transgene-driven spontaneous neuroblastoma.

Form:Solid

IC50& Target:IC50: 2.9 μM (VDR)

规格

规格或纯度
≥98%
英文名称
MeTC7
生化机理
MeTC7 是一种维生素 D 受体(VDR)拮抗剂。MeTC7 具有强效的 VDR 抑制活性,其 IC 50 值为 2.9 μM。MeTC7 具有良好的抗肿瘤效果。
储存条件
-20°C储存
运输条件
超低温运输
作用类型
拮抗剂
纯度
≥98%
名称和识别符
分子类型
小分子
分子量
618.65

技术文档

📋 安全数据表 (SDS)

全面的危险、操作、储存及法规合规文件。

下载 SDS →

✅ 分析证书 (COA)

批次质量数据。输入批号以获取对应 COA。

查询 COA →

📊 产品数据表

产品规格和应用的快速参考摘要。

查看数据表 →

🔬 规格说明书

该级别的完整质量属性和验收标准。

查看规格说明 →

高级数据

化学和物理性质
溶解性
DMSO : 16.67 mg/mL (26.95 mM; ultrasonic and warming and heat to 60°C)
质检证书(CoA,COO,BSE/TSE 和分析图谱)
C of A & Other Certificates(BSE/TSE, COO):
输入批号以搜索分析图谱:
溶液计算器